$526.06
Value $244B
LIN and PRLB stock compared: price, dividend, valuation and results, from SEC filings.
$526.06
Value $244B
$67.55
Value $1.6B
Linde (LIN) has a market value of $244B and Proto Labs (PRLB) $1.6B. Over the last year, with dividends, LIN moved +24.3% and PRLB +35.6%. The P/E is 34.8 for LIN and 45.9 for PRLB. Dividend yield: LIN 1.20%, PRLB none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
LIN$244B
PRLB$1.6B
LIN is 152 times PRLB
Revenue, 12 months
LIN$36.2B
PRLB$579M
LIN is 63 times PRLB
Net income, 12 months
LIN$7.0B
PRLB$35M
LIN is 200 times PRLB
Operating margin
LIN25.3%
PRLB7.3%
18.0 points apart
ROIC
LIN11.1%
PRLB4.5%
6.6 points apart
P/E
LIN34.8
PRLB45.9
PRLB is 1.3 times LIN
Dividend yield
LIN1.2%
PRLB0.0%
1.2 points apart
5-year return
LIN+67.0%
PRLB+14.0%
53.0 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
LIN+67.0%
PRLB+14.0%
| Period | LINWith dividends | PRLBWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | +24.3%Price +22.6% | +35.6%Price +35.6% |
| 3 years since November 13, 2023 | +36.7%+11.0% a yearPrice +31.6% | +92.6%+24.4% a yearPrice +92.6% |
| 5 years since November 12, 2021 | +67.0%+10.8% a yearPrice +56.1% | +14.0%+2.7% a yearPrice +14.0% |
| 10 years since November 15, 2016 | +430.1%+18.2% a yearPrice +349.3% | +27.6%+2.5% a yearPrice +27.6% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
LINLindePRLBProto Labs
| Price | $526.06 | $67.55 |
|---|---|---|
| Market value | $244B | $1.6B |
| Enterprise value (EV) | $265B | $1.5B |
| P/E | 34.8 | 45.9 |
| P/E, 5-year median | 32.6 | 58.3 |
| P/B | 6.2 | 2.3 |
| EV/EBIT | 28.9 | 34.3 |
| Free cash flow yield | 2.1% | 3.0% |
| Revenue, 12 months | $36.2B | $579M |
|---|---|---|
| Net income, 12 months | $7.0B | $35M |
| Free cash flow, 12 months | $5.1B | $49M |
| Earnings per share, 12 months | $15.06 | $1.43 |
| Revenue growth, year on year | 3.0% | 6.4% |
| Revenue growth a year, past | +4.5%over 5 years | +4.2%over 5 years |
| EPS growth a year, past | +25.4%over 5 years | -14.2%over 5 years |
| Gross margin | 47.9% | 45.2% |
|---|---|---|
| Operating margin | 25.3% | 7.3% |
| Net margin | 19.3% | 6.0% |
| ROIC | 11.1% | 4.5% |
| ROE | 18.1% | 5.1% |
| Cash | $3.9B | $151M |
|---|---|---|
| Total debt | $25.2B | $3.9M |
| Net debt / EBITDA | 1.7 | -2.0 |
| Interest cover | 35.5× | – |
| Dividend yield | 1.2% | – |
|---|---|---|
| Dividend per share, 12 months | $6.30 | – |
| Dividend growth a year, past | +9.3%over 5 years | – |
| Buyback yield | 1.9% | 2.7% |
| Shareholder yield | 3.1% | 2.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Linde ($244B) is about 151.8 times Proto Labs ($1.6B), at today's prices.
Since November 15, 2016, LIN's price moved +349.3% and PRLB's +27.6%. With dividends: LIN +430.1% (+18.2% a year), PRLB +27.6% (+2.5% a year). Past returns do not predict future ones.
The dividend yield at today's price is 1.20% for Linde and none for Proto Labs. Over the last twelve months they paid $6.30 and – per share.
At today's price, the P/E is 34.8 for LIN and 45.9 for PRLB. The median of the last five years was 32.6 and 58.3, which shows where each stands against its own past.
Over the last twelve months, the net margin was 19.3% for Linde and 6.0% for Proto Labs, and the operating margin 25.3% and 7.3%. Revenue was $36.2B and $579M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.